EVALUATION OF PROGNOSTIC FACTORS AND SEQUENTIAL COMBINATION CHEMOTHERAPY WITH DOXORUBICIN FOR CANINE LYMPHOMA

被引：189

作者：

KELLER, ET ^{[1
]}

MACEWEN, EG ^{[1
]}

ROSENTHAL, RC ^{[1
]}

HELFAND, SC ^{[1
]}

FOX, LE ^{[1
]}

机构：

[1] UNIV WISCONSIN,SCH VET MED,DEPT MED SCI,2015 LINDEN DR,MADISON,WI 53706

来源：

JOURNAL OF VETERINARY INTERNAL MEDICINE | 1993年 / 7卷 / 05期

关键词：

D O I：

10.1111/j.1939-1676.1993.tb01021.x

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Fifty‐five dogs with lymphoma were treated using a doxorubicin‐based sequential combination chemotherapy protocol. Complete response, partial response, and no response were seen in 46, 4, and 5 dogs, respectively. The overall median remission duration and survival times were 36 and 51 weeks, respectively. Age, sex, weight, World Health Organization stage, World Health Organization substage (i.e., a = not ill, b = ill), serum calcium concentration, blood urea nitrogen concentration, breed, and protocol alteration secondary to toxicity were evaluated for prognostic significance. Univariate analysis of prognostic factors identified sex, World Health Organization substage, and serum calcium as statistically significant (P≤ .05) variables for both survival and remission duration. Upon multivariate analysis, only substage (P= .036) was a significant prognostic factor for remission duration, whereas, both substage (P= .006) and sex (P= .005) were significant prognostic factors for survival. (Journal of Veterinary Internal Medicine 1993; 7:289–295. Copyright © 1993 by the American College of Veterinary Internal Medicine.) Copyright © 1993, Wiley Blackwell. All rights reserved

引用

页码：289 / 295

页数：7

共 24 条

[1]

MacEwen EG, Brown NO, Patnaik AK, Et al., Cyclic combination chemotherapy of canine lymphosarcoma, J Am Vet Med As-soc, 178, pp. 1178-1181, (1981)

[2]

MacEwen EG, Rosenthal RC, Fox LE, Et al., Evaluation of L‐Asparaginase: Polyethylene glycol conjugate versus native combined with chemotherapy: A randomized double blind study in canine lymphoma, J Vet Int Med, 6, pp. 230-234, (1992)

[3]

MacEwen EG, Hayes AA, Matus RE, Et al., Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978–1981), J Am Vet Med Assoc, 190, pp. 564-568, (1987)

[4]

MacEwen EG, Hayes AA, Mooney A., Et al., Levamisole as adjuvant to chemotherapy for canine lymphosarcoma, J Biol Resp Modif, 4, pp. 427-433, (1985)

[5]

Cotter SM., Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone: I. Treatment of dogs, J Am Anim Hosp Assoc, 19, pp. 159-165, (1983)

[6]

Greenlee PG, Filippa DA, Quimby FW., Et al., Lymphomas in dogs: A morphologic, immunologic, and clinical study, Cancer, 66, pp. 480-490, (1990)

[7]

Carter RF, Harris CK, Withrow SJ, Et al., Chemotherapy of canine lymphoma with histopathologic correlation: Doxorubicin alone compared to COP as first treatment regimen, J Am Anim Hosp Assoc, 23, pp. 587-596, (1987)

[8]

Postorino NC, Susaneck SJ, Withrow SJ, Et al., Single agent therapy with Adriamycin for canine lymphosarcoma, J Am Anim Hosp Assoc, 25, pp. 221-225, (1989)

[9]

Gray KN, Raulston GL, Gleiser CA, Et al., Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs, J Am Vet Med Assoc, 184, pp. 814-817, (1984)

[10]

Calvert CA, Leifer CE., Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy, J Am Vet Med Assoc, 179, pp. 1011-1012, (1981)

← 1 2 3 →